


**We claim:**

5

1. A compound of the structure



10

E is selected from the group consisting of CH<sub>2</sub>, O, S, and

NR<sup>6</sup>;

Q is selected from the group consisting of C(O) and (CH<sub>2</sub>)<sub>k</sub> wherein k is an integer of 0 or 1;

15

J is selected from the group consisting of O, S and NR<sup>8</sup>;

G is selected from the group consisting of O, NH, S, and  $(CH_2)_p$

wherein  $p$  is an integer of 0 or 1;

T is selected from the group consisting of C(O) and (CH<sub>2</sub>)<sub>b</sub> wherein b is an integer of from 0 to 3;

20

L is selected from the group consisting of O, NR<sup>7</sup>, S, and

(CH<sub>2</sub>)<sub>n</sub> wherein n is an integer of 0 or 1;

M is selected from the group consisting of  $C(R^9)(R^{10})$  and

(CH<sub>2</sub>)<sub>u</sub>, wherein u is an integer of from 0 to 3;

25


X is selected from the group consisting of  $\text{CO}_2\text{B}$ ,  $\text{PO}_3\text{H}_2$ ,  $\text{SO}_3\text{H}$ ,  $\text{OPO}_3\text{H}_2$ ,  $\text{C}(\text{O})\text{NHC}(\text{O})\text{R}^{11}$ ,  $\text{C}(\text{O})\text{NH}\text{SO}_2\text{R}^{12}$ ,

tetrazolyl and hydrogen;

B, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl,

wherein R<sup>2</sup> and R<sup>3</sup> taken together may form a ring;  
R<sup>4</sup> and R<sup>7</sup> taken together may form a ring;  
R<sup>9</sup> and R<sup>10</sup> taken together may form a ring;  
and salts thereof.

- a



LL

Q is selected from the group consisting of C(O) and (CH<sub>2</sub>)<sub>k</sub> wherein k is an integer of 0 or 1;

G is selected from the group consisting of O, NH, S, and (CH<sub>2</sub>)<sub>p</sub> wherein p is an integer of 0 or 1;

5 T is selected from the group consisting of C(O) and (CH<sub>2</sub>)<sub>b</sub> wherein b is an integer of 0 to 3;

L is selected from the group consisting of O, NR<sup>7</sup>, S, and (CH<sub>2</sub>)<sub>n</sub> wherein n is an integer of 0 or 1;

10 B, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, hydroxyalkyl, alkoxy, alkoxyalkoxy, cycloalkylalkyl, alkylamino, haloalkyl, alkylaryl, arylalkyl, heterocyclyl, alkylheterocyclyl and heterocyclylalkyl groups;

15 wherein R<sup>2</sup> and R<sup>3</sup> taken together may form a ring;  
R<sup>4</sup> and R<sup>7</sup> taken together may form a ring;  
R<sup>9</sup> and R<sup>10</sup> taken together may form a ring;  
and salts thereof.

20 5. A compound of claim 4 wherein R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are independently selected from the group consisting of hydrogen, alkoxy, alkoxyalkoxy, aryl, alkylaryl, arylalkyl, heterocyclyl and alkyl;

R<sup>4</sup> is selected from the group consisting of aryl, alkylaryl, arylalkyl, heterocyclyl, heterocyclylalkyl and alkylheterocyclyl;  
R<sup>5</sup> and R<sup>6</sup> are hydrogen; and

25 R<sup>9</sup> and R<sup>10</sup> are independently selected from the group consisting of hydrogen and lower alkyl.

30 6. A compound of claim 4 further comprising derivatives of said compound selected from the group consisting of esters, carbamates, aminals, <sup>and</sup> amides, ~~and pro-drugs~~ thereof.

a

4-

7. A compound of claim 1 selected from the group consisting of:
- (3S)-3-(1,3-benzodioxol-5-yl)-3-((((1S)-3-(methylsulfanyl)-1-  
((phenylsulfanyl)methyl)propyl)amino) carbonyl)amino)propanoic acid,  
(3S)-3-(1,3-benzodioxol-5-yl)-3-((((1S)-2-((cyclopropylmethyl)thio)-1-  
((phenylthio)methyl)ethyl)amino)carbonyl) amino)propanoic acid,  
(9S,13S)-13-(1,3-benzodioxol-5-yl)-3,11-dioxo-1-phenyl-9-[[2-  
thienylmethyl)amino]carbonyl}-2-oxa-4,10,12-triazapentadecan-15-oic  
acid, (9S,13S)-13-(1,3-benzodioxol-5-yl)-9-[[3-hydroxy-4-  
methoxybenzyl)amino]carbonyl}-3,11-dioxo-2-oxa-4,10,12-  
triazapentadecan-15-oic acid,  
(3S)-3-(1,3-benzodioxol-5-yl)-3-[[{(1S)-2-(benzylsulfanyl)-1-  
[(phenylsulfanyl)methyl]ethyl} amino)carbonyl]  
amino}propanoic acid, (3S)-3-(1,3-benzodioxol-5-yl)-3-[[{(1S)-3-  
(methylsulfanyl)-1-[(4-[(2-toluidinocarbonyl)amino]phenyl} sulfanyl  
methyl)propyl} amino)carbonyl]amino}propanoic acid, (3S)-3-(1,3-  
benzodioxol-5-yl)-3-[[{(1S)-2-(ethylsulfanyl)-1-  
[(phenylsulfanyl)methyl]ethyl} amino) carbonyl]amino}propanoic acid,  
(9S,13S)-13-(1,3-benzodioxol-5-yl)-9-[(4-[(2-  
methylbenzyl)amino]benzyl} amino)carbonyl]-3,11-dioxo-1-phenyl-2-  
oxa-4,10,12-triazapentadecan-15-oic acid, (3S)-3-(1,3-benzodioxol-5-  
yl)-3-[[{(1S)-3-(methylsulfanyl)-1-[(3-[(2-  
toluidinocarbonyl)amino]phenyl} sulfanyl)methyl]  
propyl} amino)carbonyl]amino}propanoic acid, (3S)-3-(1,3-  
benzodioxol-5-yl)-3-[[{(1S)-2-(ethylthio)-1-  
[(phenylthio)methyl]ethyl} oxy)carbonyl]amino} propanoic acid, (9S,  
13S)-13-(1,3-benzodioxol-5-yl)-3,11-dioxo-1-phenyl-9-(((4-((2-  
toluidinocarbonyl)amino)benzyl)amino)carbonyl)-2-oxa-4, 10,12-  
triazapentadecan-15-oic acid,  
and pharmaceutically acceptable salts thereof.

8. A compound of claim 7 further comprising derivatives of said compound selected from the group consisting of esters, carbamates, aminals, <sup>and</sup> amides, optical isomers <sup>and</sup> ~~and pro-drugs~~ thereof.

5 9. A pharmaceutical composition comprising:  
a compound of claim 1  
and pharmaceutically acceptable salts thereof,  
in a pharmaceutically acceptable carrier.

10 10. A method for selectively inhibiting  $\alpha_4\beta_1$  integrin binding in a mammal comprising administering to said mammal a therapeutic amount of a compound of claim 1.